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Abstract
The aim of this study was to characterize the variability of exogenous insulin require-
ments during fully closed-loop insulin delivery in hospitalized patients with type 2 dia-
betes or new-onset hyperglycaemia, and to determine patient-related characteristics
associated with higher variability of insulin requirements. We retrospectively
analysed data from two fully closed-loop inpatient studies involving adults with type
2 diabetes or new-onset hyperglycaemia requiring insulin therapy. The coefficient of
variation quantified day-to-day variability of exogenous insulin requirements during
up to 15 days using fully automated closed-loop insulin delivery. Data from 535 days
in 67 participants were analysed. The coefficient of variation of day-to-day exoge-
nous insulin requirements was 30% ± 16%, and was higher between nights than
between any daytime period (56% ± 29% overnight [11:00 PM to 4:59 AM] compared
with 41% ± 21% in the morning [5:00 AM to 10:59 AM], 39% ± 15% in the afternoon
[11:00 AM to 4:59 PM] and 45% ± 19% during the evening [5:00 PM to 10:59 PM]; all
P < 0.01). There is high day-to-day variability of exogenous insulin requirements in
inpatients, particularly overnight, and diabetes management approaches should
account for this variability.
K E YWORD S
continuous glucose monitoring (CGM), diabetes complications, insulin pump therapy, insulin
therapy, observational study, type 2 diabetes
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1 | INTRODUCTION
Safe and effective management of diabetes and stress-related hyper-
glycaemia in hospitalized patients can be challenging because of the
impact of metabolic responses to acute illness, inconsistent oral intake
and use of nutritional support, scheduled or unscheduled fasting
periods, and medications affecting insulin sensitivity, for example, cor-
ticosteroids.1,2 Exogenous insulin requirements may vary considerably
from day to day as a result of these factors. To date, characterization
of the variability of day-to-day insulin requirements in the inpatient
setting has not been reported.
Automated closed-loop insulin delivery systems can be used as a
tool to provide an estimate of exogenous insulin requirements.
Closed-loop systems incorporate an algorithm to modulate insulin
delivery in response to real-time sensor glucose levels, reflecting the
amount of insulin required to achieve in-hospital treatment targets.
Fully closed-loop insulin delivery has been evaluated in inpatients
with type 2 diabetes or new-onset hyperglycaemia in the non-critical
care setting.3–6 Randomized controlled trials comparing closed-loop
insulin delivery with usual care on the general wards have demon-
strated superior glycaemic control without increasing the risk of
hypoglycaemia, even in patients requiring enteral/parenteral nutrition
and haemodialysis.3–6
In this retrospective analysis, we quantify the day-to-day variabil-
ity of exogenous insulin delivery in adult inpatients with type 2 diabe-
tes or new-onset hyperglycaemia during a period of up to 15 days of
fully closed-loop insulin delivery.4,5 We compare patient-related char-
acteristics between those with higher and lower variability of insulin
requirements and relationship to glycaemic endpoints.
2 | RESEARCH DESIGN AND METHODS
This retrospective post hoc analysis evaluated closed-loop-directed
insulin delivery, as a marker of exogenous insulin requirements, from
two multinational randomized controlled trials.4,5
Approvals were received from independent research ethics
committees and national regulatory authorities in the UK and Swit-
zerland prior to study start. All participants provided written
informed consent. Eligible participants were adult inpatients on
non-critical care wards (medical or surgical) with type 2 diabetes or
new-onset hyperglycaemia requiring subcutaneous insulin therapy
and, for one study, there was an additional requirement for nutri-
tion support (enteral/parenteral nutrition). Inpatients with type
1 diabetes were excluded. Only data from participants assigned to
receive fully closed-loop insulin delivery were analysed in the pre-
sent study.
Participants used the FlorenceD2W-T2 closed-loop system com-
prising a Dana R insulin pump (Diabecare, Seoul, South Korea), the
Freestyle Navigator II continuous glucose monitor (Abbott Diabetes
Care, Alameda, CA, USA) and a control algorithm device containing
the model predictive control algorithm (University of Cambridge,
Cambridge, UK) continuously for up to 15 days without any meal
announcements or prandial insulin boluses. The participants' usual
insulin therapy and/or sulphonylurea medication, if prescribed, was
discontinued on the day of closed-loop initialization. All other medica-
tions were continued. Standard insulin aspart (Novorapid; Novo
Nordisk, Bagsværd, Denmark) was used in one study,4 and fast-acting
insulin aspart (Fiasp; Novo Nordisk) was used in the other.5
2.1 | Data analysis and statistical methods
Study participants with ≥4 complete days of closed-loop use were
included in the analysis. The coefficient of variation (CV) of exogenous
insulin delivery was calculated for each participant to quantify intra-
person variability of insulin requirements overall (12:00 AM to 11:59
PM), and during different periods of the day including morning (5:00
AM to 10:59 AM), afternoon (11:00 AM to 4:59 PM), evening (5:00 PM to
10:59 PM) and overnight (11:00 PM to 4:59 AM).
The overall CV was used to stratify participants into tertiles for
comparisons of demographics and glycaemic endpoints (closed-loop
performance). Pairwise comparisons were made between high and
low insulin variability groups. Data were compared using a chi-
squared test or one-way analysis of variance, with post hoc analysis
using the least significant difference test for pairwise comparisons.
Outcomes were calculated using GStat software, version 2.3
(University of Cambridge) and statistical analyses were performed
using SPSS, version 27 (IBM Software, Hursley, UK). Data are
reported as mean ± SD and P values of <0.05 were considered statis-
tically significant.
3 | RESULTS
Data from 535 inpatient days from 67 study participants were
analysed. Baseline demographics (mean ± SD) were: 69% male, age
68 ± 10 years, body mass index 32 ± 8 kg/m2, baseline glycated
haemoglobin (HbA1c) 65 ± 22 mmol/mol (8.1% ± 2.0%), and duration
of diabetes 17 ± 13 years. Of those participants included, 31.3%
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received enteral/parenteral nutrition, 13.4% haemodialysis, and
13.4% corticosteroid therapy during the study period.
The proportion of time in target glucose range between 5.6 and
10.0 mmol/L achieved with fully closed-loop delivery during the
period analysed was 67.1% ± 15.1% (mean ± SD), with time above
target glucose range (>10.0 mmol/L) 22.5% ± 15.1% and time in
hypoglycaemia (<3.9 mmol/L) 0.8% ± 0.8%. Mean sensor glucose
was 8.4 ± 1.2 mmol/L and its standard deviation 2.5 ± 0.9 mmol/L.
The total daily insulin dose was 60 ± 56 units/d with mean insulin
infusion rate 2.4 ± 2.3 units/h.
The between 24-hour period CV of insulin requirements was
30% ± 16%. The CV between night insulin requirements was higher
than between any of the daytime periods (overnight [11:00 PM to
4:59 AM] 56% ± 29% vs. morning [5:00 AM to 10:59 AM] 41% ± 21%,
afternoon [11:00 AM to 4:59 PM] 39% ± 15%, and evening [5:00 PM
to 10:59 PM] 45% ± 19%; all P <0.01). Figure 1 shows the CV of
exogenous insulin requirements during the different parts of
the day.
The mean closed-loop-directed insulin infusion rates varied
throughout the day: 2.9 ± 2.8 units/h during the morning, 3.2
± 3.9 units/h in the afternoon, 2.3 ± 2.0 units/h in the evening
and 1.6 ± 1.8 units/h during overnight periods (between groups
P = 0.012).
A post hoc test comparing high and low CV groups demonstrated
that inpatients in the highest tertile of insulin variability were younger
than those in the lowest tertile (65 ± 10 vs. 71 ± 11 years; P = 0.035).
Body mass index, gender, HbA1c, diabetes and insulin duration, use
of steroids, and requirement for dialysis or nutrition support were
comparable between the high and low insulin variability groups
(Table 1).
Participants with high variability of day-to-day insulin require-
ments had comparable mean glucose (8.3 ± 1.3 vs 8.6 ± 1.5 mmol/L;
P = 0.369) and time in target glucose 5.6 to 10 mmol/L (66.9 ± 14.3
vs 66.7% ± 19.4%; P = 0.958) to those with low variability of insulin
requirements (Table 1). There was an increase in time spent with sen-
sor glucose below 5.6 mmol/L in those with high CV of exogenous
insulin requirements (11.9 ± 6.0 vs. 8.6% ± 4.9%; P = 0.041), but no
increase in time spent in hypoglycaemia below 3.9 mmol/L in this
group compared to those with low insulin variability (0.79 ± 0.82
vs. 0.71% ± 0.80%; P = 0.690).
4 | DISCUSSION
The present analysis showed considerable variability of day-to-day
exogenous insulin requirements during use of a fully automated
closed-loop insulin delivery system in inpatients with type 2 diabetes
or new-onset hyperglycaemia.
We observed higher variability of insulin requirements between
night-time periods (CV of 56%) compared to between daytime
periods (CV of 39%-45%), in the context of lower insulin require-
ments overnight. Identifying higher-risk periods, where increased
attention needs to be given to glucose management, is important to
prevent adverse glycaemic events in inpatients. The variability of
overnight exogenous insulin requirements in people with type 2 dia-
betes or new-onset hyperglycaemia in the inpatient setting in the
present study was even greater than the variability of overnight
insulin requirements reported in adults with type 1 diabetes: 56%
compared with 31% and 36%.7,8
These results enhance our understanding of why attainment of
recommended glucose targets during the hospital admission is chal-
lenging. The workload associated with regularly adjusting insulin
doses to meet treatment goals is a significant burden in the inpatient
setting. Inpatient dysglycaemia is a poor prognostic marker, associ-
ated with increased morbidity and mortality, length of stay, and
healthcare costs.2 Our observations may help to further understand
why, despite frequent capillary blood glucose monitoring and regular
insulin dose adjustments, dysglycaemia is common in people with
type 2 diabetes and new-onset hyperglycaemia during the hospital
admission.1
High variability of insulin requirements was associated with lower
participant age in our analysis. We hypothesize that this may reflect
greater caloric intake in younger inpatients9 although other reasons
may apply. No other demographic factors significantly influenced vari-
ability of insulin requirements in our analysis.
The high day-to-day variability of insulin requirements is diffi-
cult to overcome with conventional therapeutic tools, multiple
daily injections and insulin pumps. Therefore, our results empha-
size the importance of advanced technologies such as closed-loop
systems to safely and effectively manage inpatient diabetes. The
F IGURE 1 Coefficient of variation of insulin requirements during
fully closed-loop insulin delivery. Each bar represents a different
period of the day. Data are mean ± SD. ** P <0.01
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advantage of automated, algorithm-directed insulin delivery sys-
tems is the frequent modulation of insulin delivery according to
real-time sensor glucose concentrations, thereby accommodating
variability of insulin delivery to achieve glycaemic consistency. We
have shown in this analysis that fully closed-loop insulin delivery
systems can accommodate highly variable day-to-day insulin
requirements without compromising glucose control or increasing
the risk of hypoglycaemia.
The strengths of our investigations include the heterogeneity
of participants included and the multinational study design, which
supports the generalizability of our findings. Limitations include
minor differences in study design that were not controlled for, and
a relatively short follow-up period. We did not evaluate the impact
of individual non-insulin glucose-lowering therapies. The study
was not powered to assess the impact of individual factors (dialy-
sis, nutrition support, steroid therapy) on variability of insulin
requirements.
In summary, there is high day-to-day variability of exogenous
insulin requirements in the inpatient population, particularly over-
night. Diabetes management approaches should account for this vari-
ability and consider adoption of closed-loop systems in the inpatient
setting.
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TABLE 1 Baseline demographics and glycaemic outcomes between different tertiles of variability of exogenous insulin requirements during
fully automated closed-loop insulin delivery
High CV (n = 22) Medium CV (n = 23) Low CV (n = 22) P value*
CV of insulin requirements, % 47.5 ± 13.0 27.5 ± 4.7 14.4 ± 3.9 <0.001
Male sex, n (%) 15 (68) 18 (78) 13 (59) 0.382
Age, years 64.6 ± 9.7 69.5 ± 7.7 70.7 ± 10.7 0.035
HbA1c, mmol/mol 69.2 ± 24.0 55.6 ± 10.7 70.2 ± 26.6 0.882
HbA1c, % 8.5 ± 2.2 7.2 ± 1.0 8.6 ± 2.4 0.907
Weight, kg 93.2 ± 20.5 97.3 ± 29.4 109.6 ± 42.4 0.095
BMI, kg/m2 32.9 ± 8.6 29.9 ± 5.5 34.5 ± 10.1 0.537
Duration of diabetes, years 15.0 ± 13.3 17.7 ± 12.6 18.2 ± 12.6 0.417
Duration of insulin therapy, years 6.8 ± 9.5 8.5 ± 10.2 11.8 ± 9.9 0.099
Preadmission insulin, n (%) 17 (77) 18 (78) 17 (77) 0.955
Steroids, n (%) 3 (14) 4 (17) 2 (9) 0.716
Haemodialysis, n (%) 5 (23) 2 (9) 2 (9) 0.296
Nutrition support, n (%) 5 (23) 10 (44) 6 (27) 0.286
Time spent with glucose, %
5.6-10.0 mmol/L 66.9 ± 14.3 67.7 ± 11.5 66.7 ± 19.4 0.958
>10.0 mmol/L 21.2 ± 16.2 21.6 ± 11.5 24.8 ± 17.6 0.442
<5.6 mmol/L 11.9 ± 6.0 10.7 ± 4.9 8.6 ± 4.9 0.041
<3.9 mmol/L 0.79 ± 0.82 0.79 ± 0.92 0.71 ± 0.80 0.690
Mean glucose, mmol/L 8.3 ± 1.3 8.3 ± 0.8 8.6 ± 1.5 0.369
SD glucose, mmol/L 2.5 ± 0.8 2.4 ± 0.6 2.5 ± 1.2 0.812
Total insulin dose, units/d 67.2 ± 84.3 50.8 ± 28.7 63.3 ± 39.9 0.710
Note: Data are presented as mean ± SD. *P value is post hoc test of pairwise comparison of high CV and low CV groups. Glucose data are based on sensor
glucose measurements.
Abbreviations: BMI, body mass index; CV, coefficient of variation; HbA1c, glycated haemoglobin; SD, standard deviation.
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